Choroidal Neovascularization Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Choroidal Neovascularization Treatment Market Trends and Insights

Rapid Shift to Extended-Interval Anti-VEGF

Treat-and-extend regimens now dominate real-world practice, dropping average injections per eye from 7–9 to 5–6 each year. Faricimab supports 16-week intervals for 60% of patients in its first treatment year, easing clinic congestion and travel burdens while lowering per-patient revenue.^{[1]Roche Communications, “Roche Announces TENAYA and LUCERNE Trial Extensions for Vabysmo,” Roche, roche.com}Physicians welcome the balance between fewer visits and maintained acuity, yet manufacturers must chase volume growth in cost-sensitive regions to offset revenue dilution within the choroidal neovascularization treatment market.

Expanding Access Via Anti-VEGF Biosimilars

Yesafili, Opuviz, and other aflibercept biosimilars launched in 2025 at 20–30% discounts, triggering mandatory substitution policies in Germany, France, and the United Kingdom and reaching roughly one-fifth of new-start patients within months.^{[2]European Medicines Agency, “First Aflibercept Biosimilars Recommended for Approval,” European Medicines Agency, ema.europa.eu} Japan approved Byooviz for ranibizumab in 2024, and middle-income Asia-Pacific nations rapidly followed, lifting treated volumes and broadening geographic participation in the choroidal neovascularization treatment market.

Wider OCT/OCTA Adoption and Reimbursement

Medicare broadened CPT 92134 reimbursement in 2024, propelling OCTA penetration from 20% of U.S. retina clinics in 2022 to nearly 40% in 2025.^{[3]Centers for Medicare & Medicaid Services, “Medicare Physician Fee Schedule 2024 Final Rule,” Centers for Medicare & Medicaid Services, cms.gov}OCTA detects subclinical neovascular membranes sooner than fluorescein angiography, enabling earlier therapy starts that enlarge lifetime treatment demand. Germany and France adopted similar reimbursement codes the same year, while Beijing and Shanghai pilots signal forthcoming nationwide Chinese coverage—collectively strengthening diagnostic pipelines that feed the choroidal neovascularization treatment market.

Aging Populations Expanding the nAMD Patient Pool

United Nations projections show the global 65-plus cohort rising from 770 million in 2025 to 950 million by 2031. Wet AMD prevalence escalates rapidly beyond age 70, so Japan, Germany, and Italy face sustained anti-VEGF volumes even amid unit-price erosion. This demographic engine steadies baseline revenue across mature markets and reinforces the underlying trajectory of the choroidal neovascularization treatment market.

Treatment Burden and Adherence Drop-Off

A JAMA Ophthalmology study of 12,000 Medicare enrollees showed that monthly injection regimens doubled discontinuation risk compared with quarterly schedules. Travel logistics, caregiver strain, and needle fatigue cause nearly half of patients to lapse within two years, clipping lifetime revenue potential inside the choroidal neovascularization treatment market. Depot implants aim to cut visit frequency, but surgical requirements and reimbursement gaps slow substitution.

Pricing Pressure and Reimbursement Headwinds

Medicare trimmed facility fees for intravitreal injections by up to 5% in 2025 while Germany’s AMNOG framework forced a 25% EYLEA list-price cut once biosimilars entered. Japan’s biennial revisions reduced ranibizumab reimbursement by 8% in 2024 and will shave aflibercept by 6% in 2026. Step-therapy rules now require biosimilar trials before premium approvals, slowing high-dose and dual-pathway uptake and tightening margins across the choroidal neovascularization treatment market.

Segment Analysis

By Therapeutic Modality: Originator Dominance Faces Biosimilar and Implant Pressure

Anti-VEGF originators commanded 88.36% of the choroidal neovascularization treatment market during 2025, spearheaded by Regeneron’s EYLEA, Roche’s Lucentis, and Novartis’ Beovu.. Biosimilars quickly gained 12–15% of new-start share in Europe, while sustained-delivery implants such as Susvimo are set for a 10.22% CAGR through 2031. Susvimo generated USD 45 million in 2025, with uptake capped by surgical needs and reimbursement inconsistency. Photodynamic therapy remains niche because of verteporfin shortages, and corticosteroid implants target edema-driven variants rather than mainstream CNV. Regeneron’s high-dose aflibercept achieved USD 1.2 billion in 2025 sales after proving 16-week durability, helping offset biosimilar erosion in the choroidal neovascularization treatment market.

Depot innovation continues. EyePoint adapts Durasert for anti-VEGF delivery, and Ocular Therapeutix advances a six-month tyrosine-kinase inhibitor insert. Biosimilar developers plan pre-filled syringes and auto-injectors by 2026 to streamline clinic workflows and reinforce injection dominance. Gene therapy candidates RGX-314 and ADVM-022 aim for one-time subretinal administration; if pivotal data succeed, implants and injections could face structural demand shifts after 2028, altering long-term revenue patterns in the choroidal neovascularization treatment market.

Note: Segment shares of all individual segments available upon report purchase

By Delivery Modality: Injection Entrenchment Meets Implant Upswing

Intravitreal injection held 74.24% of the choroidal neovascularization treatment market in 2025, reflecting two decades of entrenched workflow, with endophthalmitis rates below 0.05%. High-volume practices deliver 30–40 injections daily, sustaining provider revenue. Sustained-release implants are forecast to climb 9.63% per year through 2031 as patients seek fewer visits and payers weigh lifetime cost parity with higher front-loaded device spend. Verteporfin-PDT intravenous infusion has fallen below a 3% share because of drug shortages and anti-VEGF dominance, while gene therapy’s subretinal delivery remains restricted to trials. Auto-injector designs from Coherus and Samsung Bioepis promise quicker in-office turnover, reinforcing injection relevance in the choroidal neovascularization treatment market even as implants accelerate.

By Indication: Wet AMD Still Rules, Myopic CNV Accelerates

Neovascular AMD generated 66.13% of 2025 revenue and will maintain primacy as 70-plus populations expand across the G7, even though extended intervals and biosimilars compress per-patient income. Myopic CNV is projected to grow at an 8.77% CAGR through 2031, fueled by rising high-myopia prevalence in China, Japan, and South Korea. The FDA expanded aflibercept’s label to myopic CNV in 2024, and Japan approved ranibizumab for the same condition in 2023, removing reimbursement hurdles and energizing segment growth inside the choroidal neovascularization treatment market. Secondary CNV, encompassing trauma and inflammatory causes, remains small at 8–10% share but offers steady demand due to younger patient age and higher visual expectations. 

Longer life expectancy in younger myopic CNV patients increases cumulative treatment duration and amplifies interest in depot systems or future gene therapy. Under-diagnosis persists where ophthalmic imaging access is scarce, suggesting that wider OCTA availability could unlock incremental volumes for the choroidal neovascularization treatment market.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America captured 37.44% of 2025 revenue. Medicare and commercial coverage remain robust, and dense specialist networks adopt extended-interval therapy early, supporting a 5.8% CAGR through 2031 despite delayed biosimilar availability until at least 2028. Canada broadened faricimab and EYLEA HD coverage in 2025, while Mexico’s public systems lag, limiting access mainly to self-pay urban clinics. 

Automatic substitution in Germany, France, and the United Kingdom drove biosimilar share to 22% of new starts within one year, whereas Italy and Spain trail at under 12% due to slower policy roll-out. Price cuts tied to biosimilar entry shaved originator margins, yet broad reimbursement preserves high treatment penetration across major markets. 

Asia-Pacific is the fastest growth region at an 8.14% CAGR. Japan enjoys above-80% anti-VEGF uptake and rapidly integrates biosimilars, while China expanded its National Reimbursement Drug List to include both ranibizumab and aflibercept biosimilars by 2025, extending coverage beyond Tier-1 cities. India’s market remains nascent, with anti-VEGF penetration below 30% of eligible eyes, yet domestic biosimilar launches in 2026–2027 are expected to lower prices and widen adoption, further scaling the choroidal neovascularization treatment market.

The Middle East, Africa, and South America collectively contribute lesser share of global value, facing limited specialist density and reimbursement gaps. Nevertheless, private hospital chains in the Gulf states and Brazil import originator products for affluent self-pay patients, and tele-ophthalmology pilots backed by multilateral agencies may improve diagnostic reach over the forecast period, potentially adding incremental volume to the choroidal neovascularization treatment market.